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Shear induced carboplatin binding 
within the cavity of a phospholipid 
mimic for increased anticancer 
efficacy
Jingxin Mo1, Paul K. Eggers2,3, Xianjue Chen2, Muhammad Rizwan Hussain Ahamed1, 
Thomas Becker4, Lee Yong Lim1 & Colin L. Raston2
Vesicles 107 ± 19 nm in diameter, based on the self-assembly of tetra-para-phosphonomethyl calix[4]- 
arene bearing n-hexyl moieties attached to the phenolic oxygen centres, are effective in binding 
carboplatin within the cavity of the macrocycle under shear induced within a dynamic thin film in 
a continuous flow vortex fluidic device. Post shearing the vesicles maintain similar diameters and 
retain carboplatin within the cavity of the calixarene in a hierarchical structure, with their size and 
morphology investigated using DLS, TEM, SEM and AFM. Location of the carboplatin was confirmed 
using NMR, FTIR, ESI-MS and EFTEM, with molecular modelling favouring the polar groups of 
carboplatin hydrogen bonded to phosphonic acid moieties and the four member cyclobutane ring 
directed into the cavity of the calixarene. The loading efficiency and release profile of carboplatin 
was investigated using LC-TOF/MS, with the high loading of the drug achieved under shear and 
preferential released at pH 5.5, offering scope for anti-cancer drug delivery. The hierarchical 
structured vesicles increase the efficacy of carboplatin by 4.5 fold on ovarian cancer cells, lowered 
the IC50 concentration by 10 fold, and markedly increased the percent of cells in the S-phase (DNA 
replication) of the cell cycle.
Cancer is one of the biggest killers worldwide with about 8 million people dying from cancer every 
year1. Platinum based drugs have received worldwide approval in treating cancers, with carboplatin as 
a second-generation platinum based drug being safer than the traditional cisplatin while retaining a 
similar spectrum of activity. The anti-cancer activity of carboplatin arises from its binding to DNA, 
thereby inhibiting DNA synthesis and cell division2. However, there are two major limitations of carbo-
platin, its high polarity that hinders its permeation across cell membrane, and its facile degradation into 
non-active complexes by glutathione (γ -glutamylcysteinylglycine) and proteins containing methionine or 
cysteine residues. Significant breakthroughs in the next decade for platinum-based anti-cancer drugs are 
likely to come from improved chemical delivery of the already approved drugs. One delivery method is 
through vesicles3 made up of designer calix[4]arene based lipid mimics3 which are non-toxic4 and are 
potent anti-oxidants5. These vesicles can be wrapped with polymers for increased stability3 tagged with 
fluorescent molecules for tracking, tagged with targeting agents for increased delivery specificity3 and 
can intercalate non-polar drugs5 as well as store water-soluble active agents in their central core. Here 
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we report on the ability of ca 100 nm vesicles to bind a carboplatin molecule within the ‘cup’ or cavity of 
the calix[4]arene lipid mimic, which is dramatically enhanced within the shear regime of the dynamic 
thin films in a vortex fluidic device6. Such vesicles offer scope for imparting added cancer cell specificity7 
to a cancer targeting tag, as well as imparting a degree of protection to the carboplatin molecule during 
transport to the tumor. Indeed, as shown herein, the calix[4]arene lipid mimic incorporating carboplatin 
significantly increases the anti-cancer efficacy of the drug.
Results and Discussion
Design and synthesis of the calixarene. The calixarene lipid mimic (P4C6) featured herein is nec-
essarily amphiphilic, with ionisable methylphosphonic acid groups (head groups) attached to the upper 
rim of a calix[4]arene scaffold and hydrophobic n-hexyl groups (tails) attached to the lower rim phe-
nolic oxygen centers which also renders the calix[4]arene sterically restricted to the cone conformation. 
Such a calixarene can assemble in water to form micelles as small assemblies and/or vesicle bilayers 
as much larger assemblies3. For the latter, a close packed vesicle bilayer has the “cup” of the calixarene 
directed towards aqueous medium, for binding small drug molecules as host-guest complexes. P4C6 was 
prepared via modifying a method we have previously described for the synthesis of the corresponding 
n-dodecyl substituted calixarenes3 and n-octyl substituted calixarenes5. As described in detail in the 
ESI, this included standard calix[4]arene synthesis followed by addition of the n-hexyl groups through 
bromohexane and sodium hydride in DMF, formulation via the Duff reaction, reduction to the alcohol 
with sodium borohydride, chlorination with thionyl chloride, phosphorylation with triethylphosphite 
and deprotection to the final compound using bromotrimethylsilane.
Vesicle formation and carboplatin loading. The vesicles were formed by the thin-film method 
described in the methods section. Dynamic light scattering (DLS) gave a hydrodynamic diameter of 
107 ± 19 nm (Figure S1). The vesicles were loaded with carboplatin using a recently developed vortex 
fluidic device (VFD)6 which has a rapidly rotating tube open at one end (Figure S2). The high rotational 
speed generates shear in the resulting thin films arising from viscous drag, Stewartson/Ekman layers6, 
and resonance effect8, in tracking towards conditions beyond diffusion control. The constant shear in 
this microfluidic platform is effective in disassembling self-organized molecular capsules for small mol-
ecule inclusion or encapsulation,9–12 as has been established for the related spinning disc processor13. 
Moreover, the shear in the VFD is effective in being able to correctly refold proteins14. Controlling the 
re-organisation processes in the present study to bind the carboplatin was carried out in the VFD under 
the continuous flow mode. This mode incorporates scalability at the inception of the science and thus 
facilitates translation of the processing to industry requirements. In the continuous flow mode, jet feeds 
deliver reagents to the bottom of a rapidly rotating tube, typically borosilicate glass, as a standard 10 mm 
diameter NMR tube. Whirling of the liquid up the tube which is inclined relative to the horizontal 
position, creates the shear associated with the viscous drag within the dynamic thin film, and the liquid 
is collected at an exit outlet at the top. Specifically, in the present study, carboplatin dissolved in water 
(10 mM CPt) was delivered in one jet feed, and a solution of the sized vesicles (10 mM P4C6) discussed 
above was delivered in another and the combined solution was passed through the VFD three times. The 
rotational speed was set at 8000 rpm, the flow rate at 0.6 mL/min, and the inclination angle of the tube at 
45°, which are operating parameters within the regime for other inclusion/encapsulation experiments15. 
As a control, the same amount of blank P4C6 vesicle and carboplatin were sonicated for 30 minutes 
(Elma Hans Schmidbauer GmbH & Co., Singen, Germany) at 80% magnitude, without shear in the VFD. 
This resulted in only 17% host-guest complex formation after 30 minutes, and with just batch stirring 
there is almost no complexation after 48 hours. The particle size for sonication is 119 ± 13 nm, is similar 
to that for the vesicles post VFD processing.
DLS on the VFD processed P4C6 vesicles loaded with carboplatin gave a mean hydrodynamic diam-
eter of 134 ± 25 nm (Figure S3), which is consistent with transmission electron microscopy (TEM), scan-
ning electron microscopy (SEM) and atomic force microscopy (AFM), Fig. 1A-C respectively. From the 
AFM height profile, Fig. 1D, it appears that the vesicles are unilamellar, although multi-lamellar vesicles 
are also probable. As described in the ESI, micelles formed from the P4C6 via a base-acid technique 
are approximately 3 nm in diameter (Figure S4) which translates to an approximate bilayer thickness 
expected for the corresponding vesicles. The diameter of a collapsed vesicle shown in Fig. 1D is approx-
imately 7 nm which is consistent with vesicles formed using the above thin film process having two 
bilayers or unilamellar prior to collapsing.
The presence of a 1:1 P4C6-carboplatin complex within the vesicles was demonstrated by electrospray 
ionization mass spectrometry (ESI-MS) with a peak at [1508.72 m/z] (Figure S5) which corresponds to 
the [P4C6+ carboplatin+ H]+ ion (calculated [1508.52 m/z]). There was no evidence for a 2:1 complex, 
which could result from the formation of a molecular capsule based on two calixarenes encapsulating 
a single molecule of carboplatin, as established for the next largest ring system, p-phosphonated calix-
[5]arene, in aqueous medium for the same drug molecule16. Energy filtered transmission electron micros-
copy (EFTEM) was used to demonstrate that carboplatin was evenly distributed across the vesicle, with 
the unfiltered TEM, the carbon map, and the platinum map of a vesicle displayed in Fig. 1E-G respec-
tively. Elemental mapping of blank P4C6 vesicles with energy-filtered transmission electron microscopy 
(EFTEM) is presented in Figure S6.
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Fourier transform infrared spectroscopy (FTIR) shows peak shifts arising from the P4C6-carboplatin 
host-guest complex, in particular, a shift arising from NHOP hydrogen bond formation, with ν a(NH3) at 
3253 s cm−1 (Figure S7A) shifted to 3339 s cm−1 (Figure S7C) on host-guest complex formation.1H NMR 
combined with FTIR can be used to gain insight into how the carboplatin sits in the cavity of the P4C6. 
The 1H NMR spectra of carboplatin alone and the P4C6 vesicles with carboplatin are shown in Fig. 2A-C.
Figure 2A shows the chemical shifts for the protons of carboplatin attached to C1, C2 and C3, with 
the triplet at 2.72 ppm assigned to the CH2 groups at C1 and C3 and the quintuplet at 1.74 ppm to the 
CH2 at C2. After host-guest complex formation (Fig. 2B,C) the carboplatin CH2 resonances for C1 and 
C3 shift 0.36 ppm upfield, while the CH2 resonance for C2 shifts 0.09 ppm downfield. The upfield shift 
is consistent with a shielding effect within the cavity of the P4C6, with the protons directed over the face 
of the aromatic rings. The deshielding of the C2 protons is consistent with the unique methylene group 
being directed to the centre of the cavity, closer to the O-alkyl chains. Combined with the shifts from 
hydrogen bonding for FTIR data, the most likely host-guest complex structure is shown in Fig. 2, along 
with an energy minimized molecular model.
The molecular model in Fig.  2 was produced by first minimizing the energy of free P4C6 and car-
boplatin individually using MOPAC2012 semi-empirical PM7. The minimized P4C6 and carboplatin 
were then manually docked together in the host-guest model, for binding and energy minimization. The 
Figure 1. VFD processed P4C6-carboplatin host-guest vesicles: (A) TEM image, scale bar 500 nm (10 nm 
for inset), (B) SEM image, scale bar 600 nm, (C) AFM image, (D) sectional height profile of a collapsed 
vesicle and elemental mapping of host-guest complex with energy-filtered transmission electron microscopy 
(EFTEM) for (E) unfiltered, (F) carbon and (G) platinum.
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optimized geometry gave a final heat of formation of -1168 Kcal/mol. The MOPAC2012 semi-empirical 
PM7 model of the host-guest complex indicates that the hydrophobic interaction between the carbopla-
tin bridging ligand and the cavity of the P4C6 are complemented by six intermolecular hydrogen bonds 
between the nitrogen and oxygen atoms in carboplatin and the opposing phosphonic acid groups on 
the calixarene (NH···OP; 1.9-2.0 Å. POH···O; 1.7-2.1 Å). Indeed, the flexible phosphonate groups serve 
to anchor the drug molecule in the cavity through extended hydrogen bonding. As indicated by the 
molecular model, Fig.  2, the carboplatin C2 sits centrally within the expected deshielding region with 
the C1 and C3 protons located above the plane of calixarene phenolic groups, within the shielding 
region of the aromatic rings. This geometry is consistent with the above 1H NMR data, which shows a 
more pronounced upfield shift for the hydrogen atoms at C1 and C3, and a small downfield shift for the 
hydrogen atoms at C2, as well as the FTIR which shows a shift in ν (NH) arising from hydrogen bonding.
Integration of the 1H NMR spectrum established that the shear within the VFD gave 75% incorpora-
tion of the carboplatin within the cavity of the available P4C6, whereas probe sonication for 30 minutes 
resulted in only 17% incorporation (Fig.  2B,C). This is despite the short processing time for a finite 
volume of liquid moving through the VFD under continuous flow three times, being less than three 
minutes6. Presumably the intense micro-mixing and subsequent shear in the VFD results in the majority 
of the P4C6 molecules on the solution face of the bilayer (immediately accessible) to bind carboplatin. 
Given that 50% of the P4C6 cavities point towards the centre of the vesicle, and yet 75% of them become 
Figure 2. Schematic of the binding of carboplatin within the cavity of P4C6, MOPAC2012 PM7 geometry 
optimized model of the P4C6-carboplatin complex and 1H NMR spectra of (A) carboplatin, (B) carboplatin 
with 1.0 equivalent of P4C6 after probe sonication, and (C) carboplatin with 1.0 equivalent of P4C6 after 
VFD processing.
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occupied with carboplatin, there must be some disruption of the bilayer taking place in the dynamic 
thin film produced by the VFD. Disassembly of the vesicles under shear can be ruled out since the size 
distribution of the vesicles remained relatively similar before and after VFD processing (Figure S1 and 
S3), and disassembly of the vesicle is expected to result in a large size distribution. The complex shear 
regimes produced by the VFD6 may induce an increase in lipid mobility where P4C6 molecules with the 
head groups facing the interior of the vesicles undergo a flip to the side facing the exterior and vice versa. 
This would allow P4C6-carboplatin host-guest complexes to be on the inside layer of the vesicle as well 
as the outside layer, in tracking towards 75% binding of the carboplatin molecules. The constant shear 
during the VFD processing allows for intimate contact of free carboplatin with the flipped calixarene 
molecules. In contrast the application of sonication induces localized short-lived cavitation events which 
are ineffective in exposing the inner calixarene cavities to the carboplatin.
The carboplatin loading in the P4C6 vesicles was also quantified by LC-TOF/MS using a literature 
adapted method17. Under set electrospray ionization conditions, carboplatin was predominantly the pro-
tonated fragment ([C5H10NO2Pt]+), and the MS parameters were optimized to maximize the response 
for the production of m/z 310.0152 (Figure S8). The standard curve for carboplatin was calculated to 
be y = 0.23x + 78.06 (R2 = 0.996) (Figure S9). The percent drug loading efficiency (DL) was calculated 
from the mass of carboplatin in a host-guest complex (mCPt) and the mass of host-guest complex (mHG) 
according to:





The loading efficiency of carboplatin within the cavity of the P4C6-carboplatin host-guest vesicles 
was established at 24 ± 2% (W/W), as determined for three separately prepared vesicles suspensions. 
This loading, which is higher than that determined using.1H NMR spectroscopy, equates to approxi-
mately 1.02 P4C6 per carboplatin molecule post shearing. We hypothesize that 75% of the associated 
carboplatin is encapsulated within a host-guest complex and the remaining 25% of the carboplatin is 
hydrogen-bonded to the surface without binding in the cavity of the calixarenes. Furthermore, the high 
rate of lipid flipping within the VFD processing may enable adsorbed carboplatin to be transferred to 
the centre of the vesicle.
Release of carboplatin from P4C6-carboplatin host-guest vesicles. In ascertaining the potential 
of the system for carboplatin delivery, its release profile from the host-guest vesicles was investigated 
using dialysis bags and PBS at pH 5.5 or 7.4 as receiving medium (Fig. 3).
The P4C6-carboplatin host-guest vesicles (CPt-P4C6) were relatively stable at pH 7.4, with about 
20% of loaded carboplatin released after 2 days at 37 °C (Fig. 3). In contrast, at pH 5.5, approximately 
20% of carboplatin was released from the vesicle during the initial 5 h, which represents a 10-fold faster 
release rate. The increased carboplatin release by the vesicles under acidic conditions relates to the pKa 
of the phosphonic acid head groups which is 7.216. Thus, at pH 7.4 the phosphonic acid head groups are 
deprotonated and hence take on a negative charge whereas at pH 5.5 the head groups are predominantly 
fully protonated and hence neutral. The loss of charge in acidic conditions is associated with a decrease 
in polarity of the head groups and suggests that the vesicles will be destabilized within an aqueous envi-
ronment relative to the mildly basic pH 7.4. These findings are promising for targeting cancer chemo-
therapy as the pH within a tumor is typically between pH 5.5 and 7.0, compared to a pH of 7.5 in normal 
tissues18. This suggests that the vesicles will have a greater stability in systemic circulation at the pH of 
normal tissues, with potential for more rapid carboplatin release following extravasation to tumorigenic 
tissues where the pH decreases in the extracellular milieu and in cytoplasmic lysosome.
Figure 3. Release profile of carboplatin (CPt) from CPt-P4C6 host-guest vesicles at pH 7.4 and pH 5.5 over 
48 h (n = 3) (Mean ± SD). Statistical analysis was performed using a Student’s t-test. Values of *P < 0.05 and 
**P < 0.01 were considered statistically significant.
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Efficacy of P4C6-carboplatin host-guest vesicles. The efficacy of the P4C6-carboplatin vesicles 
was investigated through cell vitality studies on the SKOV-3 ovarian cancer cell line to calculate the 
half-maximal inhibitory concentration (IC50). The IC50 in this case gives a quantitative measure of the 
concentration of P4C6, free carboplatin (CPt), and carboplatin loaded in P4C6 vesicles (CPt-P4C6) 
required to kill 50% of the ovarian cancer cells. In preliminary experiments we found no significant dif-
ference (P > 0.05) between flow cytometry and MTT data. The IC50 of CPt, P4C6 and CPt-P4C6 against 
the SKOV-3 cells were determined using a FITC-Annexin V/Dead Cell Apoptosis Kit.
As can be seen in Fig. 4A-E, the IC50 data in Fig. 4B demonstrates that for the same cytotoxic effect 
a 10 fold lower concentration of carboplatin is required if it is combined with the P4C6 vesicle (3.8 μ M 
for CPt vs. 0.35 μ M for CPt-P4C6). Furthermore, this is not due to toxicity of the P4C6 as a 200 fold 
higher concentration of P4C6 alone (78 μ M) is required to get the same effect as CPt-P4C6. This high 
efficacy is also reflected in the flow cytometric analysis shown in Fig. 4C-E where CPt-P4C6 results in 
16.3% live cells at 1 μ M, compared to 72.3% live cells at 1 μ M of CPt. Thus there is a 4.5 fold increase in 
cell mortality by loading the carboplatin into the vesicles. This increase is also not due to the toxicity of 
P4C6, with the flow cytometric analysis results showing 82.5% live cells for P4C6 at 5 μ M. The collective 
data suggests that CPt is more efficiently delivered into the cells when it is associated with P4C6.
Figure 4. Carboplatin-P4C6 induced apoptosis of SKOV-3 cells and caused cell arrest in the S phase. 
(A) Dose-response curves for P4C6, CPt (= carboplatin) and CPt-P4C6 against SKOV-3 cells after 24 h 
incubation, and (B) corresponding IC50 for P4C6, CPt and CPt-P4C6. Flow cytometric analysis of SKOV-3 
cells treated with (C) 5 μ M P4C6, (D) 1 μ M CPt, and (E) 1 μ M CPt-P4C6 for 24 h followed by treatment 
with the reagents in the Dead Cell Apoptosis Kit. (F) Cell cycle analysis of SKOV-3 cells treated for 12 h 
with negative control (cell culture media), 5 μ M P4C6, 1 μ M CPt, and 1 μ M CPt-P4C6. Statistical analysis 
was performed using a Student’s t-test. Values of *P < 0.05 and ***P < 0.005 were considered statistically 
significant.
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Mechanism of action for the P4C6-carboplatin host-guest vesicles. CPt binds with DNA to 
form intrastrand crosslinks and adducts which activates a number of biochemical pathways that lead 
eventually to cell cycle arrest in the S phase, followed by cell recovery, apoptosis and cell death depending 
on the extent of DNA damage. In general the cell cycle is classified into five phases: the G0, G1, S, G2 and 
the M phases. The G0 is when the cell has left the cycle, G1 is the growth phase, S is the DNA replication 
phase, G2 is the gap between DNA synthesis and cell division, and M is the phase where cell division 
occurs. We investigated whether CPt associated with P4C6 vesicles (CPt-P4C6) is able to retain the same 
cell cycle modulation effect as CPt by using PI staining. Whereas flow cytometric analysis of blank P4C6 
vesicles–treated SKOV-3 cells showed no cell cycle effects after 12 h of treatment, an increased percentage 
of cells in the S and G2/M phases and a corresponding decrease in G0/G1 cells were observed following 
12 h of treatment with CPt and CPt-P4C6. (Fig. 4F) Compared to CPt, the CPt-P4C6 host-guest complex 
led to an increase of cells in the S phase from 21.2 ± 4.9% to 40.5 ± 9.9% and a decrease of cells in the 
G0/G1 phase from 42.8 ± 5.8% to 23.5 ± 4.6%. These data suggest that the increased effect of CPt-P4C6 
on SKOV-3 cell proliferation resulted from an increase of the fraction of cells in the S phase, which is 
consistent with the mechanism of action of CPt. This result combined with previous findings shows the 
P4C6-carboplatin vesicles to be an effective platform for facilitating the delivery of carboplatin into the 
cell nucleus.
Summary. We have established that the sparingly water soluble amphiphilic phosphonated calixarene 
lipid mimic P4C6 self-assembles into stable vesicles above 100 nm in diameter within a polar solvent. 
The vesicles can bind the water-soluble anti-cancer drug carboplatin within the cavity of the calixarenes 
which are restricted to be in the cone conformation, with 75% binding efficiency using a vortex fluidic 
device (VFD) under continuous flow mode of processing, which further highlights the versatility of this 
processing technology. The binding of the carboplatin in P4C6 was investigated using 1H NMR, FTIR, 
ESI-MS, EFTEM, TEM, SEM and AFM, establishing a 1:1 P4C6 to carboplatin complex which represents 
a high loading efficiency of the drug. The host-guest complex has high stability in pH 7.4 biosample 
media, with flow cytometric analysis establishing that the carboplatin-P4C6 host-guest vesicles result in 
a 4.5 fold increase in efficacy at 1 μ M and a 10 fold lower IC50 relative to carboplatin in the absence of 
the P4C6. When treated with CPt-P4C6, more cells were stopped in the S phase implying P4C6 vesicles 
are a highly efficient delivery system for carboplatin.
The calixarene lipid mimic vesicles offer a number of promising features for anticancer drug delivery 
applications, including (1) they can be tagged with a targeting agent, a fluorescent molecule or wrapped 
in a polymer without reducing the vesicle stability3 (2) they can transport polar agents like carboplatin19 
in their interior space and non-polar drugs like curcumin4, by intercalation or encapsulation, (3) the 
phosphonated calixarene is non-toxic4 and a potent anti-oxidant5, (4) their diameter is an optimal size for 
targeting cancerous tissue7, (5) they are relatively stable at normal tissue pH but rapidly release the drug 
molecule at typical cancerous tissue close to pH 6, and (6) that they increase the efficiency of carboplatin 
on ovarian cancer cells 4.5 fold.
After injection into the body, the vesicles are prone to elimination from systemic circulation by the 
reticuloendothelial system. This can be overcome by linking the vesicles to folic acid through a PEG moi-
ety, noting that such PEGylation of vesicles can prolong residence time in the body, decrease degradation 
by metabolic enzymes and reduce or eliminate protein immunogenicity.
Methods
Blank P4C6 Vesicles Synthesis. Blank P4C6 vesicles were synthesised by a thin film method of 
preparation. P4C6 (17 g, 15 mmol) was weighed and dissolved in chloroform (50 ml) with ultrasonication 
for 5 minutes (FXP8D ultrasonic cleaner, Unisonics Australia, Brookvale, NSW, AUS). The solution was 
attached to a Buchi Rotavapor® R-215 (Flawil, Switzerland) to allow the evaporation of the organic sol-
vent at 55° over 150 minutes. The resultant thin film was rehydrated in MilliQ water to give the desired 
P4C6 concentration (10 mM). Rehydration was performed by ultrasonication for 5 minutes followed by 
probe sonication (VCX130 ultrasonic processor, Sonics and Materials Inc. Newton, CT, USA) at 80% 
amplitude for 10 minutes to allow for the assembly of the nanoparticles. The final vesicles dispersion was 
filtered through a 0.45 μ m PES Membrane filter (Millipore Corporation, Darmstadt, Germany).
Carboplatin-P4C6 Binding. Vortex Fluidic Device (VFD). Carboplatin (371 mg, 1 mmol) dissolved 
in water (100 ml) to give a 10 mM solution. This solution was delivered in one jet feed and a solution 
of the sized vesicles (10 mM P4C6) was delivered the second jet feed and passes through the VFD. The 
combined solution was passed through the VFD two more times. The rotational speed of the VFD was 
set at 8000 rpm, the flow rate at 0.6 mL/min, and the inclination angle of the tube at 45°. The superna-
tant vesicle dispersion was centrifuged (Heraeus Megafuge 40R Refrigerated Centrifuge, Thermo Fisher 
Scientific Inc., MA, USA) at 25,000 g for 30 min to precipitate the P4C6-carboplatin host-guest vesicles. 
The resultant pellet was washed twice with PBS (pH 7.4). The pellet was then suspended in PBS (pH 7.4) 
to make the final stock concentration of 10 mM CPt-P4C6 vesicles for further use.
Sonication. Blank P4C6 vesicles (5 mL, 10 mM) and carboplatin (5 mL, 10 mM) were mixed and then 
sonicated for 30 minutes (Elma Hans Schmidbauer GmbH & Co., Singen, Germany) at 80% magnitude. 
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The supernatant dispersion was centrifuged (Heraeus Megafuge 40R Refrigerated Centrifuge, Thermo 
Fisher Scientific Inc., MA, USA) at 25,000 g for 30 min to precipitate the P4C6-carboplatin host-guest 
vesicles. The resultant pellet was washed twice with PBS (pH 7.4). The pellet was then suspended in PBS 
(10 ML, pH 7.4).
Drug Release. The 10 mM stock solution of VFD loaded carboplatin-P4C6 vesicles (2.5 ml) was injected 
into a dialysis bag (Spectrum Laboratories, Inc., Rancho Dominguez, CA, cut off molecular weight of 
3500 Da) containing PBS (1000 ml) buffered to pH 5.5 or 7.4 and with 1% Tween 80 and 0.5% FBS, at 
37.5 °C. At specific intervals the release medium around the dialysis bag was sampled (5 mL) for analysis 
by the established LC/TOF MS method mentioned below17.
LC/MS. Chromatography was performed using a WATERS Prominence (Waters MS Technologies, 
Manchester, UK) equipped with a 100 × 3.0 mm Symmetry C18 3.5 μ m column (Sunfire, Waters Corp, 
Milford, USA). Mass spectrometry was performed on a Micromass LCT Premier system (Waters MS 
Technologies, Manchester, UK) operating in positive ion mode. Gradient elution of a mobile phase com-
prising acetonitrile (A) and 1 mM aqueous sodium acetate (B) was delivered at a flow rate of 0.25 ml/
min as follows: 0 – 3 min: 20% A; 3 – 6 min, linear increase of A from 20% to 80%; 6 – 9 min: 80% A; 
9 to 12 min, linear decrease of A from 80% to 20%. Calibration standard solutions were prepared by 
appropriate dilutions of stock solutions of CPT (in water). The total analytical time was only 12 min. 
Detection and quantitation were performed by electrospray ionization (ESI) in the positive ionization 
mode with Selective Ion Monitoring (SIM) at m/z 310.0152. The calibration curves were linear over the 
concentration range of 10-4000 ng/ml, with the respective lower limit of quantification (LLOQ) at 10 ng/
ml. The intra- and inter-day precision and accuracy of analysis of the quality control samples at low, 
medium, and high concentration levels were ≤ 13.6% relative standard deviation (RSD) and ≤ 14.6% 
relative errors (RE).
IC50. The SKOV-3 cells were seeded in 6-well plates (2 mL/well) with a concentration of 1 × 106 cells/mL 
in McCoy’s 5 A (modified) media (Life Technologies, San Diego, CA) and were incubated for 24 h in a 
humidified atmosphere containing 5% CO2 at 37 °C. The media in the wells was then replaced with pre-
pared growth media (2 mL) which also contained P4C6, carboplatin or P4C6-carboplatin complex at var-
ious concentrations. The treated cells were incubated for a further 24 h, after which the sample-containing 
media was removed by aspiration. Cells in the media were collected by centrifugation on 275 g for 3 min. 
The remaining cell layers were washed with PBS buffer (2 × 1 mL). The total cells from cultures were 
differentially stained with Dead Cell Apoptosis Kit (Life Technologies, San Diego, CA) which contained 
two fluorescent dyes (Annexin V FITC and PI), allowing assessment of the viable, dead, and apoptotic 
cells. The number of viable cells was counted by a BD FACSCalibur flow cytometer (Becton, Dickinson 
and Company, Franklin Lake, NJ, USA) and was plotted against the total P4C6 or carboplatin concentra-
tion in logarithmic scale. The data reported represent an average of three measurements from different 
batches. The dose-response curves shown in Fig.  4 were obtained by sigmoidal logistic fitting using 
Origin 8.5 (OriginLab Corporation, Northampton, MA,USA) and the half-maximal inhibitory concen-
tration (IC50) values were determined on the basis of the fitted data.
Cell Cycle Analysis. Samples-induced effects on SKOV-3 cells cycle were analysed using a FACS Calibur 
Flow Cytometer (Becton, Dickinson and Company, Franklin Lake, NJ, USA) with the BD Bioscience 
CellQuest Pro software (Becton, Dickinson and Company, Franklin Lake, NJ, USA). After exposure three 
different samples for 12 h SKOV-3 cells were harvested for counting of cell numbers.
Wash cells by centrifugation (300 g, 5 min, 4 °C) in PBS. Resuspend 2 × 106 cells in 1 ml ice cold PBS. 
Vortex gently and slowly adding the cell suspension dropwise to an equal volume of cold absolute etha-
nol. Store at 4 °C to –40 °C for overnight. Centrifuge cells at 300 g for 10 min at 4 °C. Resuspend pellet in 
3 ml cold PBS and transfer to FalconTM12 × 75 mm (FAL352003) polystyrene tubes for staining.
Wash cells at least once with cold PBS. Resuspend cells in 300 - 500 μ l PI/Triton X-100 (Sigma-Aldrich 
Corporation, St. Louis, MO, USA) staining solution. Incubate 37 °C for 15 minutes. Transfer tubes to ice 
or store at 4 °C protected from light. Acquire data on flow cytometer and FlowJo software (FlowJo. LLC, 
Ashland, Oregon, USA) is used to fit the data to various cell cycle models.
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